Qin, Y., Gao, G., Xie, X., Zhu, Z., Guan, W., Lin, X., et al. (2019) Clinical Features and Prognosis of Pulmonary Lymphoepithelioma-Like Carcinoma: Summary of Eighty-Five Cases. Clinical Lung Cancer, 20, e329-e337.
https://doi.org/10.1016/j.cllc.2018.12.014

has been cited by the following article:

• TITLE: Primary Pulmonary Lymphoepithelioma-Like Carcinoma Demonstrates a Favorable Response to Tislelizumab Combined with Chemotherapy: A Case Report

  AUTHORS: Qianglong Lin, Xiaofen Ma

  KEYWORDS: Primary Pulmonary Lymphoepithelioma-Like Carcinoma, LELC, Tislelizumab, Immune Checkpoint Inhibitor

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.2, February 13, 2025

  ABSTRACT: Background: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare subtype of non-small cell lung cancer (NSCLC). Nevertheless, no universally acknowledged standards of care have been reported to be effective and productive for the treatment of this tumor. Materials and Methods: A patient with advanced primary pulmonary LELC was treated by employing a combination of tislelizumab and chemotherapy. Results: The patient displayed a favorable response to the combination therapy. The tumor size exhibited conspicuous abatement in contrast to the pre-treatment baseline, and the tumor markers normalized. Conclusion: The combination of immunotherapy with chemotherapy appears to be more effective than therapy alone for managing advanced primary pulmonary LELC. On that account, further clinical trials are imperative to establish this combination regimen as a potential first-line treatment option for advanced cases.